107 related articles for article (PubMed ID: 8841014)
21. Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
Hartmann LC; Lindor NM
N Engl J Med; 2016 Jun; 374(24):2404. PubMed ID: 27305204
[No Abstract] [Full Text] [Related]
22. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
[TBL] [Abstract][Full Text] [Related]
23. Prophylactic surgery in hereditary breast/ovarian cancer syndrome.
Levine DA; Gemignani ML
Oncology (Williston Park); 2003 Jul; 17(7):932-41; discussion 946-8, 950-2. PubMed ID: 12886864
[TBL] [Abstract][Full Text] [Related]
24. Patient-reported quality of life following prophylactic surgery for breast and ovarian cancer prevention: response.
Wei X; Oxley S; Sideris M; Legood R; Manchanda R
Am J Obstet Gynecol; 2024 Feb; 230(2):274-275. PubMed ID: 37659746
[No Abstract] [Full Text] [Related]
25. Lessons learned from genetic testing.
Esserman L; Kaklamani V
JAMA; 2010 Sep; 304(9):1011-2. PubMed ID: 20810382
[No Abstract] [Full Text] [Related]
26. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
[TBL] [Abstract][Full Text] [Related]
27. Genetic counselling and prophylactic surgery in women from families with hereditary breast or ovarian cancer.
Lobb E; Meiser B
Lancet; 2004 Jun; 363(9424):1841-2. PubMed ID: 15183619
[No Abstract] [Full Text] [Related]
28. [Prophylactic surgery of mammary and ovarian carcinoma].
Lux MP; Bani MR; Fasching PA; Beckmann MW
Chirurg; 2005 Dec; 76(12):1145-54. PubMed ID: 16237564
[TBL] [Abstract][Full Text] [Related]
29. [Hereditary breast cancer: treatment and prevention].
Ejlertsen B; Gerdes AM
Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871
[TBL] [Abstract][Full Text] [Related]
30. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
[TBL] [Abstract][Full Text] [Related]
31. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
Dowdy SC; Stefanek M; Hartmann LC
Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
[TBL] [Abstract][Full Text] [Related]
32. Variation in prophylactic surgery decisions.
Julian-Reynier C; Eisinger F; Evans G; Foulkes W; Sobol H
Lancet; 2000 Nov; 356(9242):1687. PubMed ID: 11089849
[No Abstract] [Full Text] [Related]
33. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
Hartmann LC; Lindor NM
N Engl J Med; 2016 Feb; 374(5):454-68. PubMed ID: 26840135
[No Abstract] [Full Text] [Related]
34. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer.
Hermsen BB; van Diest PJ; Berkhof J; Menko FH; Gille JJ; Piek JM; Meijer S; Winters HA; Kenemans P; Mensdorff-Pouilly Sv; Verheijen RH
Int J Cancer; 2006 Sep; 119(6):1412-8. PubMed ID: 16615107
[TBL] [Abstract][Full Text] [Related]
35. [Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation].
Synowiec A; Wcisło G; Bodnar L; Szczylik C
Ginekol Pol; 2012 Jan; 83(1):51-6. PubMed ID: 22384640
[TBL] [Abstract][Full Text] [Related]
36. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.
Wainberg S; Husted J
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):1989-95. PubMed ID: 15598752
[TBL] [Abstract][Full Text] [Related]
37. Sexual Health Is Paramount in the Counseling of Women at Risk for Breast or Ovarian Cancer Undergoing Risk-Reducing Surgery.
Rullo JE; Pruthi S
J Natl Compr Canc Netw; 2017 Nov; 15(11):1297-1299. PubMed ID: 29118222
[No Abstract] [Full Text] [Related]
38. Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer.
Eisinger F; Geller G; Burke W; Holtzman NA
Lancet; 1999 Mar; 353(9156):919-20. PubMed ID: 10094000
[No Abstract] [Full Text] [Related]
39. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
40. Characterizing biased cancer-related cognitive processing: relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery.
Carpenter KM; Eisenberg S; Weltfreid S; Low CA; Beran T; Stanton AL
Health Psychol; 2014 Sep; 33(9):1003-11. PubMed ID: 23772886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
